{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:28:59Z","timestamp":1794068939658,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The standard for clinical staging of lung cancer is the use of CT and PET scans, however, these may underestimate the burden of the disease. The use of serum tumor markers might aid in the detection of subclinical advanced disease. The aim of this study is to review the predictive value of tumor markers in patients with clinical stage I NSCLC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A comprehensive search was performed using the Medline, EMBASE, Scopus data bases. Abstracts included based on the following inclusion criteria: 1) adult \u226518\u2009years old, 2) clinical stage I NSCLC, 3) Tumor markers (CEA, SCC, CYFRA 21-1), 4) further imaging or procedure, 5)\u2009&gt;\u20095 patients, 6) articles in English language. The primary outcome of interest was utility of tumour markers for predicting nodal involvement and oncologic outcomes in patients with clinical stage I NSCLC. Secondary outcomes included sub-type of lung cancer, procedure performed, and follow-up duration.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Two hundred seventy articles were screened, 86 studies received full-text assessment for eligibility. Of those, 12 studies were included. Total of 4666 patients were involved. All studies had used CEA, while less than 50% used CYFRA 21-1 or SCC. The most common tumor sub-type was adenocarcinoma, and the most frequently performed procedure was lobectomy. Meta-analysis revealed that higher CEA level is associated with higher rates of lymph node involvement and higher mortality.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>There is significant correlation between the CEA level and both nodal involvement and survival. Higher serum CEA is associated with advanced stage, and poor prognosis. Measuring preoperative CEA in patient with early stage NSCLC might help to identify patients with more advanced disease which is not detected by CT scans, and potentially identify candidates for invasive mediastinal lymph node staging, helping to select the most effective therapy for patients with potentially subclinical nodal disease. Further prospective studies are needed to standardize the use of CEA as an adjunct for NSCLC staging.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13019-020-01353-2","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T20:02:46Z","timestamp":1602792166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Elevated preoperative CEA is associated with subclinical nodal involvement and worse survival in stage I non-small cell lung cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6878-2852","authenticated-orcid":false,"given":"Awrad","family":"Nasralla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"#cr-split#-1353_CR1.1","doi-asserted-by":"crossref","unstructured":"Barta JA, Powell CA, Wisnivesky JP, Glob A, Author H. Global Epidemiology of Lung Cancer HHS Public Access Author manuscript. Ann Glob Heal. 2019;85","DOI":"10.5334\/aogh.2419"},{"key":"#cr-split#-1353_CR1.2","unstructured":"(1) [cited 2020 Feb 25]. Available from: http:\/\/creativecommons.org\/licenses\/by\/4.0\/."},{"issue":"1","key":"1353_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-019-0731-8","volume":"12","author":"C Zhang","year":"2019","unstructured":"Zhang C, Leighl NB, Wu Y-L, Zhong W-Z. Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019;12(1):45 [cited 2020 Feb 25]. Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0731-8.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1353_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.cllc.2018.04.011","volume":"19","author":"S Andersson","year":"2018","unstructured":"Andersson S, Ilonen I, J\u00e4rvinen T, Rauma V, R\u00e4s\u00e4nen J, Salo J. Surgically Treated Unsuspected N2-Positive NSCLC: Role of Extent and Location of Lymph Node Metastasis. Clin Lung Cancer. 2018;19(5):418\u201325 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29880414.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"1353_CR4","first-page":"11295","volume":"8","author":"F Chen","year":"2015","unstructured":"Chen F, Wang X-Y, Han X-H, Wang H, Qi J. Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of early-stage NSCLC from benign lung disease. Int J Clin Exp Med. 2015;8(7):11295\u2013300 [cited 2020 Feb 25]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26379938.","journal-title":"Int J Clin Exp Med"},{"key":"#cr-split#-1353_CR5.1","doi-asserted-by":"crossref","unstructured":"McDonald F, De Waele M, Hendriks LEL, Faivre-Finn C, Dingemans A-MC, Van Schil PE. Management of stage I and II nonsmall cell lung cancer. Eur Respir J. 2017;49","DOI":"10.1183\/13993003.00764-2016"},{"key":"#cr-split#-1353_CR5.2","unstructured":"(1) [cited 2020 Feb 25]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28049169."},{"issue":"11","key":"1353_CR6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/MNM.0000000000000903","volume":"39","author":"GE Aktas","year":"2018","unstructured":"Aktas GE, Karamustafao\u011flu YA, Balta C, S\u00fct N, Sarikaya \u0130, Sarikaya A. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer. Nucl Med Commun. 2018;39(11):995\u20131004 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30188416.","journal-title":"Nucl Med Commun"},{"key":"1353_CR7","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M, Gimferrer JM, et al. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography\/computer tomography scan. Eur J Cardiothorac Surg. 2010;37(5):1168\u20131174 [cited 2020 May 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20116273.","DOI":"10.1016\/j.ejcts.2009.12.013"},{"issue":"7","key":"1353_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s11748-019-01263-8","volume":"68","author":"A D'Andrilli","year":"2020","unstructured":"D'Andrilli A, Maurizi G, Venuta F, Rendina EA. Mediastinal staging: when and how? Gen Thorac Cardiovasc Surg. 2020;68(7):725\u201332. https:\/\/doi.org\/10.1007\/s11748-019-01263-8.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"2","key":"1353_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.athoracsur.2018.02.054","volume":"106","author":"SR Turner","year":"2018","unstructured":"Turner SR, Seyednejad N, Nasir BS. Patterns of Practice in Mediastinal Lymph Node Staging for Non-Small Cell Lung Cancer in Canada. Ann Thorac Surg. 2018;106(2):428\u201334 [cited 2020 Feb 25]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29596820.","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"1353_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.athoracsur.2014.03.004","volume":"97","author":"HJ Cho","year":"2014","unstructured":"Cho HJ, Kim SR, Kim HR, Han J-O, Kim Y-H, Kim DK, et al. Modern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancer. Ann Thorac Surg. 2014;97(6):1920\u20135 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24768044.","journal-title":"Ann Thorac Surg"},{"issue":"18","key":"1353_CR11","doi-asserted-by":"publisher","first-page":"e3568","DOI":"10.1097\/MD.0000000000003568","volume":"95","author":"F Yang-Chun","year":"2016","unstructured":"Yang-Chun F, Min F, Di Z, Yan-Chun H. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People\u2019s Republic of China. Medicine (Baltimore). 2016;95(18):e3568 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27149479.","journal-title":"Medicine (Baltimore)"},{"key":"1353_CR12","unstructured":"Yu H, Huang X, Zhu Z, Hu Y, Ou W, Zhang L, et al. Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma. Chin J Cancer Res [Internet]. 2014;26(1):89\u201394 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24653630."},{"issue":"4","key":"1353_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1164\/rccm.201404-0603OC","volume":"193","author":"R Molina","year":"2016","unstructured":"Molina R, Marrades RM, Aug\u00e9 JM, Escudero JM, Vi\u00f1olas N, Reguart N, Ramirez J, Filella X, Molins L, Agust\u00ed A. Assessment of a combined panel of six Serum tumor markers for Lung Cancer. Am J Respir Crit Care Med. 2016;193(4):427\u201337. https:\/\/doi.org\/10.1164\/rccm.201404-0603OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"#cr-split#-1353_CR14.1","doi-asserted-by":"crossref","unstructured":"Decaluw\u00e9 H, Dooms C, D'Journo XB, Call S, Sanchez D, Haager B, et al. Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study. Eur Respir J. 2017;50","DOI":"10.1183\/13993003.01493-2017"},{"key":"#cr-split#-1353_CR14.2","unstructured":"(6) [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29269579."},{"issue":"6","key":"1353_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/thx.2006.062760","volume":"63","author":"T Hishida","year":"2008","unstructured":"Hishida T, Yoshida J, Nishimura M, Nishiwaki Y, Nagai K. Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer. Thorax. 2008;63(6):526\u201331 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18024539.","journal-title":"Thorax"},{"issue":"1 Suppl","key":"1353_CR16","doi-asserted-by":"publisher","first-page":"137S","DOI":"10.1378\/chest.123.1_suppl.137S","volume":"123","author":"EM Toloza","year":"2003","unstructured":"Toloza EM, Harpole L, DC MC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123(1 Suppl):137S\u201346S [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12527573.","journal-title":"Chest"},{"issue":"6","key":"1353_CR17","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1378\/chest.130.6.1791","volume":"130","author":"RJ Cerfolio","year":"2006","unstructured":"Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest. 2006;130(6):1791\u20135 [cited 2020 May 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17166998.","journal-title":"Chest"},{"issue":"3","key":"1353_CR18","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0003-4975(02)04638-6","volume":"75","author":"G Buccheri","year":"2003","unstructured":"Buccheri G, Ferrigno D. Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test. Ann Thorac Surg. 2003;75(3):973\u201380 [cited 2020 Feb 28]. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497502046386.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"1353_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0169-5002(02)00009-0","volume":"36","author":"N Reinmuth","year":"2002","unstructured":"Reinmuth N, Brandt B, Semik M, Kunze W-P, Achatzy R, Scheld HH, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer. 2002;36(3):265\u201370 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12009236.","journal-title":"Lung Cancer"},{"key":"1353_CR20","doi-asserted-by":"crossref","unstructured":"Suzuki K, Nagai K, Yoshida J, Moriyama E, Nishimura M, Takahashi K, et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg [Internet]. 1999;67(4):927\u2013932 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10320230.","DOI":"10.1016\/S0003-4975(99)00140-X"},{"issue":"1","key":"1353_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lungcan.2011.02.001","volume":"74","author":"T Hanagiri","year":"2011","unstructured":"Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer. 2011;74(1):112\u20137 [cited 2020 May 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21397974.","journal-title":"Lung Cancer"},{"issue":"2","key":"1353_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.athoracsur.2006.07.079","volume":"83","author":"W-H Hsu","year":"2007","unstructured":"Hsu W-H, Huang C-S, Hsu H-S, Huang W-J, Lee H-C, Huang B-S, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg. 2007;83(2):419\u201324 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17257963.","journal-title":"Ann Thorac Surg"},{"issue":"S3","key":"1353_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/1097-0142(197809)42:3+<1477::AID-CNCR2820420818>3.0.CO;2-E","volume":"42","author":"JP Concannon","year":"1978","unstructured":"Concannon JP, Dalbow MH, Hodgson SE, Headings JJ, Markopoulos E, Mitchell J, et al. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma. Cancer. 1978;42(S3):1477\u201383 [cited 2020 May 30]. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/10970142(197809)42:3+%3C1477::AID-CNCR2820420818%3E3.0.CO;2-E.","journal-title":"Cancer"},{"issue":"11","key":"1353_CR24","first-page":"CD009519","volume":"2014","author":"M Schmidt-Hansen","year":"2014","unstructured":"Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqu\u00e9 I, Figuls M. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Datab Syst Rev. 2014;2014(11):CD009519 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25393718.","journal-title":"Cochrane Datab Syst Rev"},{"key":"1353_CR25","doi-asserted-by":"crossref","unstructured":"Kuo Y-S, Zheng M-Y, Huang M-F, Miao C-C, Yang L-H, Huang T-W, et al. Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression. Sci Rep [Internet]. 2020;10(1):2066 [cited 2020 May 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32034239.","DOI":"10.1038\/s41598-020-59031-1"},{"issue":"1","key":"1353_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0003-4975(02)03662-7","volume":"74","author":"N Sawabata","year":"2002","unstructured":"Sawabata N, Ohta M, Takeda S, Hirano H, Okumura Y, Asada H, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non- small cell lung cancer. Ann Thorac Surg. 2002;74(1):174\u20139 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12118753.","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"1353_CR27","first-page":"490","volume":"4","author":"J Wang","year":"2012","unstructured":"Wang J, Ma Y, Zhu Z-H, Situ D-R, Hu Y, Rong T-H. Expression and prognostic relevance of tumor carcinoembryonic antigen in stage IB non-small cell lung cancer. J Thorac Dis. 2012;4(5):490\u20136 [cited 2020 may 30]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23050113.","journal-title":"J Thorac Dis"},{"issue":"4","key":"1353_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/clinchem\/34.4.761","volume":"34","author":"JS Nisselbaum","year":"1988","unstructured":"Nisselbaum JS, Smith CA, Schwartz D, Schwartz MK. Comparison of Roche RIA, Roche EIA, Hybritech EIA, and Abbott EIA methods for measuring carcinoembryonic antigen. ClinChem. 1988;34(4):761\u20134 Available from: https:\/\/doi.org\/10.1093\/clinchem\/34.4.761.","journal-title":"ClinChem"},{"issue":"1","key":"1353_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21037\/jtd.2017.01.30","volume":"9","author":"R Maeda","year":"2017","unstructured":"Maeda R, Suda T, Hachimaru A, Tochii D, Tochii S, Takagi Y. Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer. J Thorac Dis. 2017;9(1):176\u201386. https:\/\/doi.org\/10.21037\/jtd.2017.01.30.","journal-title":"J Thorac Dis"},{"issue":"1","key":"1353_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12885-015-1068-5","volume":"15","author":"Y Takahashi","year":"2015","unstructured":"Takahashi Y, Horio H, Sakaguchi K, Hiramatsu K, Kawakita M. Significant correlation between urinary N1, N12-diacetylspermine and tumor invasiveness in patients with clinical stage IA non-small cell lung cancer. BMC Cancer. 2015;15(1):65 [cited 2020 Feb 28]. Available from: http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1068-5.","journal-title":"BMC Cancer"},{"issue":"2","key":"1353_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1510\/icvts.2009.206698","volume":"9","author":"R Kawachi","year":"2009","unstructured":"Kawachi R, Nakazato Y, Takei H, Koshi-ishi Y, Goya T. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembryonic antigen level predict pathological stage? Interact Cardiovasc Thorac Surg. 2009;9(2):199\u2013202 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19457896.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"1","key":"1353_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.athoracsur.2013.03.050","volume":"96","author":"S Cho","year":"2013","unstructured":"Cho S, Song IH, Yang HC, Kim K, Jheon S. Predictive Factors for Node Metastasis in Patients With Clinical Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg. 2013;96(1):239\u201345 [cited 2020 Feb 28]. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497513006309.","journal-title":"Ann Thorac Surg"},{"issue":"12","key":"1353_CR33","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1007\/s00268-016-3652-5","volume":"40","author":"K Kaseda","year":"2016","unstructured":"Kaseda K, Asakura K, Kazama A, Ozawa Y. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography. World J Surg. 2016;40(12):2976\u201383 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27456499.","journal-title":"World J Surg"},{"issue":"6","key":"1353_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/jso.23293","volume":"107","author":"T Kato","year":"2013","unstructured":"Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, et al. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: Differences according to histology and smoking status. J Surg Oncol. 2013;107(6):619\u201324 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23192365.","journal-title":"J Surg Oncol"},{"issue":"8","key":"1353_CR35","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1097\/JTO.0b013e31825871de","volume":"7","author":"T Koike","year":"2012","unstructured":"Koike T, Koike T, Yamato Y, Yoshiya K, Toyabe S-I. Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients. J Thorac Oncol. 2012;7(8):1246\u201351 [cited 2020 Feb 25]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22659962.","journal-title":"J Thorac Oncol"},{"key":"1353_CR36","first-page":"309","volume":"11","author":"H Komatsu","year":"2013","unstructured":"Komatsu H, Mizuguchi S, Izumi N, Chung K, Hanada S, Inoue H, et al. Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer. World J SurgOncol. 2013;11:309 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24313932.","journal-title":"World J SurgOncol"},{"issue":"6","key":"1353_CR37","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/ejcts\/ezu363","volume":"47","author":"Y Tsutani","year":"2015","unstructured":"Tsutani Y, Murakami S, Miyata Y, Nakayama H, Yoshimura M, Okada M. Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung. Eur J Cardio-Thoracic Surg. 2015;47(6):1022\u20136 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25293403.","journal-title":"Eur J Cardio-Thoracic Surg"},{"issue":"1","key":"1353_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.athoracsur.2014.03.005","volume":"98","author":"B Ye","year":"2014","unstructured":"Ye B, Cheng M, Li W, Ge X-X, Geng J-F, Feng J, et al. Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2014;98(1):217\u201323 [cited 2020 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24841547.","journal-title":"Ann Thorac Surg"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-020-01353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-020-01353-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-020-01353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T15:42:49Z","timestamp":1634312569000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-020-01353-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1186\/s13019-020-01353-2","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent does not apply for this type of study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}